Molecular basis of agonism and antagonism in the oestrogen receptor

Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery,. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17β-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 Å, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.

[1]  M. Beato,et al.  Interaction of steroid hormone receptors with the transcription initiation complex. , 1996, Endocrine reviews.

[2]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[3]  B. Katzenellenbogen,et al.  Different Residues of the Human Estrogen Receptor Are Involved in the Recognition of Structurally Diverse Estrogens and Antiestrogens* , 1997, The Journal of Biological Chemistry.

[4]  D. Ciocca,et al.  Estrogen receptors in human nontarget tissues: biological and clinical implications. , 1995, Endocrine reviews.

[5]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[6]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[7]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[8]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[9]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[10]  B. Katzenellenbogen,et al.  Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. , 1993, Molecular endocrinology.

[11]  H W Cole,et al.  Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. , 1997, Journal of medicinal chemistry.

[12]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[13]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[14]  M. Parker,et al.  Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[16]  C. Arnaud,et al.  A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  S. Fawell,et al.  Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor , 1990, Cell.

[18]  P. Chambon,et al.  Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.

[19]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  John A. Katzenellenbogen,et al.  The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site , 1997, Steroids.

[21]  M. Parker,et al.  RIP-140 interacts with multiple nuclear receptors by means of two distinct sites , 1996, Molecular and cellular biology.

[22]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[23]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[24]  H. Witkowska,et al.  Carboxymethylation of the human estrogen receptor ligand-binding domain-estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid , 1996, Steroids.

[25]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[26]  B. Katzenellenbogen,et al.  Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[28]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[29]  B. Katzenellenbogen,et al.  Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation* , 1996, The Journal of Biological Chemistry.